(Q28287239)
Statements
Class III beta-tubulin isotype predicts response in advanced breast cancer patients randomly treated either with single-agent doxorubicin or docetaxel (English)
Carlos M Galmarini
Isabelle Treilleux
Virginie Durbecq
David Gancberg
Marie-Christine Bissery
Marianne Paesmans
Denis Larsimont
Martine J Piccart
Chantal Bernard-Marty